John Baker, MD
Neurology · Sumter, SCNPI 1598922130
Payments from drug & device makers
Across 2,670 payments — averaging $291.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$122K
- Neurocrine Biosciences, Inc.$103K
- Teva Pharmaceuticals USA, Inc.$103K
- EMD Serono, Inc.$78K
- Amgen$54K
- Sanofi$39K
- plus $280K from 54 others
What the payments were for
- Consulting fees$62,2648%
- Speaking & faculty fees$639,15482%
- Travel & lodging$31,5834%
- Food & beverage$44,8966%
- Education$1,5790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$95,630
- INGREZZA$94,407
- Mavenclad$75,046
- QULIPTA$56,684
- NURTEC ODT$41,371
- AIMOVIG$38,311
- AUSTEDO$37,166
- Austedo XR$34,819
- AUBAGIO$29,252
- ZEPOSIA$25,836
- AJOVY$25,384
- VYEPTI$23,138
- ZAVZPRET$22,067
- Fycompa$19,549
- REXULTI$17,969
- Nayzilam$15,080
- PURIFIED CORTROPHIN GEL$12,699
- BRIUMVI$12,280
- VALTOCO$10,439
- Ponvory$9,788
How this compares
$779,476 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 44 | $1,262,322 |
| Austedo XrDeutetrabenazine | 94 | $688,406 |
| IngrezzaValbenazine Tosylate | 77 | $612,078 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 22 | $458,515 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 30 | $405,361 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $334,544 |
| Kesimpta PenOfatumumab | 28 | $276,334 |
| TecfideraDimethyl Fumarate | 22 | $211,339 |
| RytaryCarbidopa/Levodopa | 169 | $204,155 |
| Radicava OrsEdaravone | 14 | $202,534 |
| Teriflunomide | 53 | $176,072 |
| AustedoDeutetrabenazine | 13 | $131,999 |
| AubagioTeriflunomide | 13 | $119,547 |
| GilenyaFingolimod Hcl | 11 | $112,268 |
| FinteplaFenfluramine Hcl | 13 | $106,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $2,766 | $1,262,32244 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Copaxone | $102,676 | $899,794121 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $102,907 | $612,07877 claims |
| CSL BehringPrivigen | $488 | $334,54421 claims |
| BiogenTecfidera, Vumerity | $837 | $311,16134 claims |
| UCB, Inc.Fintepla, Neupro, Briviact | $18,826 | $211,626101 claims |
| Amneal Pharmaceuticals LLCRytary | $5,076 | $204,155169 claims |
| SanofiAubagio | $39,296 | $119,54713 claims |
| NovartisGilenya | $9,982 | $112,26811 claims |
| MDD US Operations, LLCGocovri | $336 | $102,00232 claims |
| Kyowa Kirin, Inc.Nourianz | $149 | $61,96128 claims |
| AbbVieUbrelvy, Namzaric | $121,585 | $61,19442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 270 neurology providers in South Carolina.
Other neurology in Sumter
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
- Howard MandellRock Hill$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.